1. Pink Sheet
  2. >>Geography

WHO To Advise On Formulation Of Next COVID-19 Vaccines

 
• By Ian Schofield

The Technical Advisory Group on COVID-19 Vaccine Composition is to hold two more meetings this year and may make recommendations on how new vaccines should be formulated.

What is the best incentive to develop new antimicrobials? • Source: Shutterstock

An advisory group to the World Health Organization is to look at whether future COVID-19 vaccines will still need to include the index (original) SARS-CoV-2 virus as well as its later variants and says that any further recommendations on updating vaccine composition will be issued at its next meeting in May.

In the meantime, it “remains prudent” to try to achieve broader cross-reactive vaccine-induced immune responses, and manufacturers should continue to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

UK HRA Sets Targets For Digital Overhaul, Trial Transparency And Trust

 
• By Vibha Sharma

The UK Health Research Authority’s latest three-year strategy sets ambitious targets to make research more transparent. One World Health Organization official believes the authority can go further by setting equally high standards for the timely reporting of clinical trial results.

Valneva Expects UK And France to Lift Ixchiq Age Restriction Following EMA Decision

 
• By Anabel Costa-Ferreira

Other authorities are expected to mirror the European Medicines Agency’s decision to lift the temporary restriction it placed on using Valneva’s chikungunya vaccine in people aged 65 years and older.

US FDA’s Second Half 2025 User Fee Goals Swing Toward Respiratory Disease

 
• By Bridget Silverman

The 43 novel agents with user fee goal dates in the remainder of 2025 have fewer oncologics and infectious disease drugs than the first half of the year